Search the Newsreel

IMUNON Advances OVATION 3 Trial Of IMNN-001; Enrollment Expected To Complete In 1H29

(RTTNews) - IMUNON, Inc. (IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, reported its second-quarter 2026 financial results and provided a business update, with investors focusing on continued progress in the pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian …

Replimune Group, Inc. (REPL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz announced that investors who suffered losses with Replimune Group, Inc. (REPL) have the opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that between October 20, 2025, and April 10, 2026, Replimune made false …

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

Pomerantz LLP has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) for alleged securities fraud. The lawsuit comes after the FDA rejected Replimune's Biologics License Application for RP1, citing several deficiencies in its studies, leading to significant drops in the company's …

Replimune Group, Inc. (REPL) stock price, news, quote and history

This Yahoo Finance page provides a comprehensive overview of Replimune Group, Inc. (REPL) stock, including its current price, news headlines, and performance data. The stock is listed on NasdaqGS and shows recent fluctuations based on FDA decisions regarding its drug candidates. News articles detail …

Earnings call transcript: Imunon beats Q2 2026 EPS forecast as shares stay weak

Imunon (IMNN) reported a smaller-than-expected loss of $0.54 per share in Q2 2026, surpassing analyst estimates of a $0.93 loss. Despite the beat, the stock remained under pressure due to investor concerns about cash needs, its early-stage clinical pipeline, and the long road ahead …

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) for alleged securities fraud. The lawsuit, covering the period from October 20, 2025, to April 10, 2026, claims Replimune made misleading statements by failing to disclose …

Imunon, Inc. 2Q 2026: Net loss $(2.83M), EPS $(0.54) — 10-Q Summary

Imunon, Inc. reported a net loss of $(2.83M) and an EPS of $(0.54) for the second quarter of 2026. The company ended the quarter with $11.86M in cash and restricted cash but expressed substantial doubt about its ability to continue as a going concern. …

Imunon reports Q2 2026 net loss $2.8M; cash $6.9M, advances Phase 3 OVATION 3

Imunon reported a Q2 2026 net loss of $2.8 million and cash and cash equivalents of $6.9 million as of June 30, 2026. The company is advancing its Phase 3 OVATION 3 study for lead candidate IMNN-001, citing accelerated enrollment and positive clinical signals. …

IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update

IMUNON, Inc. reported its second-quarter 2026 financial results, highlighting significant progress in the Phase 3 OVATION 3 study for its lead candidate IMNN-001 for ovarian cancer. The company noted rapid enrollment exceeding expectations and new preliminary data from a Phase 2 MRD study showing …

Optimum Communications (OPTU): Evaluating a Tender Offer Arbitrage

Investment management company Curreen Capital released its second-quarter 2026 Investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund returned 22.26% compared to 15.20% for the S&P 500 Index. The performance was driven by active special case …

IMUNON reports $2.8 million Q2 loss as OVATION 3 enrollment advances

IMUNON (IMNN) reported a net loss of $2.8 million, or $0.54 per share, for Q2 2026, with operating expenses remaining unchanged from the previous year. The company is advancing its Phase 3 OVATION 3 study for ovarian cancer, with enrollment expected to conclude by …

Yimutian announces annual shareholder meeting

Yimutian will hold its annual general meeting in Beijing on August 31, 2026, where shareholders will vote on proposed resolutions. The board of directors supports these proposals and recommends voting in favor. This news brief was generated by Public Technologies using AI based on …

Transaksi Saham Guna Timur (TRUK) Kembali Dibuka, Bakal Lanjutkan Kenaikan?

Yimutian Inc. (Nasdaq: YMT) seeks 1,000-vote Class B shares and 200B authorized shares

Yimutian Inc. is calling an annual general meeting on August 31, 2026, to vote on significant changes to its capital structure and governance. Key proposals include increasing the voting power of Class B ordinary shares from 20 to 1,000 votes each, expanding the authorized …

Form 8K Imunon Inc For: 11 August By Investing.com

This article reports on the filing of Form 8K by Imunon Inc. on August 11. It briefly mentions that the information is provided by Investing.com. The piece also includes some unrelated popular news headlines and market data.

Replimune Prices $150 Million Underwritten Offering

(RTTNews) - Replimune Group, Inc. (REPL), a commercial-stage biotechnology company developing oncolytic immunotherapies, announced the pricing of an underwritten offering of 9,701,490 shares of its common stock at $12.06 per share. In addition, the company is issuing pre-funded warrants, equal to the offering price …

Optimum Q2 Earnings Miss Tests Its 2026 Outlook and Cost Discipline

Is OPTU Stock a Buy as Mobile Growth Meets Debt and Revenue Risks?

Optimum Communications, Inc. OPTU is expanding its mobile business, improving operating efficiency and investing in network modernization. However, declining residential revenue, elevated leverage and negative free cash flow complicate the investment case. The stock's Zacks Rank and Style Scores point to a setup that …

OPTU Stock Falls 28% in a Month: Is the Weakness an Opportunity?

Shares of Optimum Communications, Inc. OPTU have declined 28% in the past month, putting the spotlight on whether the sharp pullback reflects deteriorating fundamentals or creates an opportunity if the company's operational initiatives gain traction. Compared with larger telecom peers such as AT&T Inc. …

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false and misleading statements regarding its …

Replimune Group stock hits 52-week high at 13.92 USD

Replimune Group stock has reached a 52-week high of $13.92, driven by a 128% one-year return and recent FDA accelerated approval for its cancer treatment TUDRIQEV. While analysts have upgraded the stock and increased price targets, InvestingPro suggests the shares may be overvalued, and …

Did Lowered 2026 Guidance After VA Incentive Pause Just Shift Maximus' (MMS) Investment Narrative?

Maximus, Inc. (MMS) recently lowered its fiscal 2026 guidance following a pause in performance incentives on its VA Medical Disability Exam program. This decision highlights the company's reliance on structured government contracts, which can significantly impact earnings despite improving quarterly EPS and a strong …

Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months

Replimune Group's stock has surged nearly 223% in the past three months, primarily due to the FDA's accelerated approval of its lead oncolytic immunotherapy, RP1 (Tudriqev), for advanced melanoma. This approval, in combination with Bristol Myers' Opdivo, marks a significant commercial milestone for Replimune …

Replimune prices $150M underwritten offering of common stock and pre-funded warrants

Replimune (REPL) has priced an underwritten offering to raise approximately $150.0 million in gross proceeds. The offering includes 9,701,490 shares of common stock and pre-funded warrants for 2,736,340 shares, priced at $12.06 per share. Net proceeds are estimated to be around $140.5 million after …

Janus Henderson Group PLC Decreases Holdings in Maximus, Inc. $MMS

Janus Henderson Group PLC significantly reduced its stake in Maximus, Inc. by 95.4% in the first quarter, selling nearly half a million shares. Despite this, Maximus exceeded fiscal Q3 EPS expectations but saw revenue decline year-over-year and lowered its fiscal 2026 EPS guidance, leading …

Replimune in the spotlight: Earnings loom days after FDA approval

Replimune Group Inc. is set to report its fiscal fourth-quarter earnings, marking its first financial update since receiving FDA approval for its melanoma therapy, Tudriqev. Despite the regulatory success, analysts have significantly lowered EPS estimates, though most still rate the stock a "Buy" with …

Maximus (NYSE:MMS) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Maximus (NYSE:MMS) announced its quarterly earnings, reporting an adjusted EPS of $2.22, exceeding analyst expectations by $0.01, though revenue of $1.28 billion missed estimates and was down 5.1% year-over-year. The company lowered its fiscal 2026 adjusted EPS guidance to $7.90–$8.20, partially due to a …

Optimum Communications Q2 Earnings Call Highlights

Key Points Interested in Optimum Communications, Inc.? Here are five stocks we like better. Mobile growth partly offset broadband weakness: Optimum added approximately 50,000 mobile lines, bringing the total to 724,000, while broadband net losses improved sequentially to 40,000. Video losses also improved to …

Two Rejections, Messy Process: Replimune Finally Secures FDA Approval for Skin Cancer Treatment

The FDA has granted accelerated approval to Replimune Group Inc. for its novel oncolytic immunotherapy, Tudriqev, for advanced cutaneous melanoma. This approval comes after previous rejections and relies on promising clinical trial results from the IGNYTE trial, which showed a 24.2% objective response rate …

Maximus Q3 Earnings Call Highlights

Key Points Interested in Maximus, Inc.? Here are five stocks we like better. Maximus lowered its full-year earnings and cash-flow guidance after the Department of Veterans Affairs paused performance incentives on its Medical Disability Exam program. Adjusted EPS is now expected at $7.90–$8.20 and …

MAXIMUS Inc (NYSE:MMS): A Sustainable Dividend for Quality-Focused Investors

Law Offices of Frank R. Cruz Encourages Replimune Group, Inc. (REPL) Shareholders To Inquire About Securities Fraud Class Action

The Law Offices of Frank R. Cruz has filed a class action lawsuit against Replimune Group, Inc. (REPL) on behalf of shareholders who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made materially false and misleading statements …

Reinhart Partners LLC. Purchases 1,127,346 Shares of Maximus, Inc. $MMS

Reinhart Partners LLC. significantly increased its stake in Maximus, Inc. (NYSE:MMS) by 131.8% in the second quarter, acquiring an additional 1.13 million shares to hold nearly 2 million shares valued at $106.6 million. This makes Maximus its 18th largest holding, representing 2.4% of its …

Optimum Communications (OPTU) Stock Faces Debt Strain Despite Record Margins

Maximus (MMS) Stock Profit Gains Meet VA Incentive Hit

Maximus (MMS) Stock Looks Reasonable Following Its 32% YTD Decline

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Maximus has had a difficult start to the year, with the share price down 31.5% year to date. However, valuation checks suggest the …